Eli Lilly And Co
- All
- News
-
3 Indian Firms To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
-
Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients.
-
US Drugmaker To Donate 400,000 Covid Treatment Tablets To India
Eli Lilly and Co said on Tuesday it would supply 400,000 tablets of its COVID-19 treatment, to be used with Gilead's remdesivir, to India as the country fights a raging pandemic that has morgues and hospitals overflowing.
-
Lilly's COVID-19 Drug Could Be Ready For Use As Soon As September
Eli Lilly and Co could have a drug specifically designed to treat COVID-19 authorized for use as early as September if all goes well with either of two antibody therapies it is testing, its chief scientist told Reuters on Wednesday.
-
Government's Plan To Pull In 324 Companies Including Tesla, Glaxo: Report
The government is planning to offer 324 companies including Tesla Inc. and GlaxoSmithKline Plc incentives to set up factories in India in a bid to capitalize from the trade war between China and the US., according to a document seen by Bloomberg.
-
Top generic drugmakers look to US as patents end
India's top drugmakers, among the world's biggest producers of cheap generic medicines, are looking beyond their own shores to generate revenue, seeking to profit from big-selling drugs going off-patent this year in the lucrative U.S. market.
-
Drug maker Eli Lilly to cut 1,000 US sales jobs: report
Drug maker Eli Lilly and Co plans to lay off about 1,000 domestic sales representatives, or 30 per cent of its US sales force, as it faces new generic competition for its top drugs, a person familiar with the matter said on Friday.
-
Piramal buys Bayer's potential Alzheimer's drug
5,135-5,150 remain immediate support levels though medium term supports are pegged at 5,070.
-
3 Indian Firms To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
-
Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients.
-
US Drugmaker To Donate 400,000 Covid Treatment Tablets To India
Eli Lilly and Co said on Tuesday it would supply 400,000 tablets of its COVID-19 treatment, to be used with Gilead's remdesivir, to India as the country fights a raging pandemic that has morgues and hospitals overflowing.
-
Lilly's COVID-19 Drug Could Be Ready For Use As Soon As September
Eli Lilly and Co could have a drug specifically designed to treat COVID-19 authorized for use as early as September if all goes well with either of two antibody therapies it is testing, its chief scientist told Reuters on Wednesday.
-
Government's Plan To Pull In 324 Companies Including Tesla, Glaxo: Report
The government is planning to offer 324 companies including Tesla Inc. and GlaxoSmithKline Plc incentives to set up factories in India in a bid to capitalize from the trade war between China and the US., according to a document seen by Bloomberg.
-
Top generic drugmakers look to US as patents end
India's top drugmakers, among the world's biggest producers of cheap generic medicines, are looking beyond their own shores to generate revenue, seeking to profit from big-selling drugs going off-patent this year in the lucrative U.S. market.
-
Drug maker Eli Lilly to cut 1,000 US sales jobs: report
Drug maker Eli Lilly and Co plans to lay off about 1,000 domestic sales representatives, or 30 per cent of its US sales force, as it faces new generic competition for its top drugs, a person familiar with the matter said on Friday.
-
Piramal buys Bayer's potential Alzheimer's drug
5,135-5,150 remain immediate support levels though medium term supports are pegged at 5,070.
